RxDoctor Payments Data

Daniel Hilton, MD

Internal Medicine · Huntington Beach, CANPI 1093811358

Payments from drug & device makers

$688in general payments, 2019–2025

Across 31 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$140
  • AbbVie$59
  • CMP Pharma, Inc.$48
  • Abbott$48
  • Teva Pharmaceuticals USA, Inc.$42
  • Kowa Pharmaceuticals America, Inc.$40
  • plus $311 from 15 others

What the payments were for

  • Food & beverage$688100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$688 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,181,042
Medicare patients
482
Services billed
12,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate14$119,881
EliquisApixaban257$112,591
CreonLipase/Protease/Amylase43$39,799
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$28,959
SantylCollagenase Clostridium Hist.32$21,802
JardianceEmpagliflozin48$21,711
LinzessLinaclotide38$19,561
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog100$19,125
XareltoRivaroxaban26$18,577
JanuviaSitagliptin Phosphate20$17,927
Budesonide80$17,801
OzempicSemaglutide16$14,966
MyrbetriqMirabegron31$13,611
MounjaroTirzepatide11$11,827
RestasisCyclosporine18$11,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis, Lumigan$59$75,660110 claims
Boehringer IngelheimJardiance, Tradjenta$26$25,65663 claims
Johnson & JohnsonXarelto$140$18,57726 claims
Lilly USA, LLCMounjaro, Humalog$15$16,39272 claims
Novo NordiskOzempic$17$14,96616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Huntington Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →